CA2392353A1 - Compositions pharmaceutiques stables au benzimidazole labile acide - Google Patents

Compositions pharmaceutiques stables au benzimidazole labile acide Download PDF

Info

Publication number
CA2392353A1
CA2392353A1 CA002392353A CA2392353A CA2392353A1 CA 2392353 A1 CA2392353 A1 CA 2392353A1 CA 002392353 A CA002392353 A CA 002392353A CA 2392353 A CA2392353 A CA 2392353A CA 2392353 A1 CA2392353 A1 CA 2392353A1
Authority
CA
Canada
Prior art keywords
composition according
vitamin
acid labile
derivative
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002392353A
Other languages
English (en)
Inventor
Arthur M. Deboeck
Francis Van Der Biest
Philippe R. Baudier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GALEPHAR PHARMACEUTICAL RESEARCH Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2392353A1 publication Critical patent/CA2392353A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une nouvelle formulation pharmaceutique orale stable renfermant un composé benzimidazole labile acide, stabilisé au moyen d'un dérivé de vitamine E. Plus spécialement, la composition renferme le composé benzimidazole labile acide en solution et/ou en suspension dans de l'huile et/ou des dérivés d'huile, et un dérivé de vitamine E comme stabilisateur. Un mode de réalisation particulier comprend l'oméprazole comme composé benzimidazole labile acide et le succinate de polyéthylèneglycol comme dérivé du stabilisateur de vitamine E.
CA002392353A 1999-11-22 2000-11-22 Compositions pharmaceutiques stables au benzimidazole labile acide Abandoned CA2392353A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16676199P 1999-11-22 1999-11-22
US60/166,761 1999-11-22
PCT/IB2000/001842 WO2001037834A1 (fr) 1999-11-22 2000-11-22 Compositions pharmaceutiques stables au benzimidazole labile acide

Publications (1)

Publication Number Publication Date
CA2392353A1 true CA2392353A1 (fr) 2001-05-31

Family

ID=22604612

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002392353A Abandoned CA2392353A1 (fr) 1999-11-22 2000-11-22 Compositions pharmaceutiques stables au benzimidazole labile acide

Country Status (4)

Country Link
EP (1) EP1259238A1 (fr)
AU (1) AU1545301A (fr)
CA (1) CA2392353A1 (fr)
WO (1) WO2001037834A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010015143A1 (de) * 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (fr) * 1986-02-13 1994-02-15 Tadashi Makino Compositions pharmaceutiques contenant un compose anti-ulcereux de type benzimidazole et sa production
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
EP1049459B1 (fr) * 1998-01-20 2009-04-22 Applied Analytical Industries, Inc. Compositions liquides orales

Also Published As

Publication number Publication date
EP1259238A1 (fr) 2002-11-27
AU1545301A (en) 2001-06-04
WO2001037834A1 (fr) 2001-05-31

Similar Documents

Publication Publication Date Title
EP1108425B1 (fr) Nouvelles préparations pharmaceutiques multi-unitaires stables contenant des benzimidazoles substitués
EP1061920B1 (fr) Formulation pharmaceutique comportant un 2- (2- pyridinyl) methyl] sulfinyl] benzimidazole dote d'une activite anti-ulcereuse et procede de preparation de cette formulation
KR100510366B1 (ko) 위보호성 오메프라졸 마이크로그래뉼, 이것의 제조방법 및약학적 제제
US20080311204A1 (en) Stable oral formulation containing benzimidazole derivative
WO1999061022A1 (fr) Composition pharmaceutique orale stable contenant un pyridylsulfinyl benzimidazole substitue
PL186605B1 (pl) Tabletka lub mikrotabletka zawierająca rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol oraz sposób wytwarzania tabletek lub mikrotabletek zawierających rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol
JP2011157390A (ja) 胃液において不溶性の微小顆粒、その調製方法、および薬学的調製物
AU2002210284A1 (en) Stable oral formulation containing benzimidazole derivative
US20070196463A1 (en) Enteric Soft Gelatin Capsule Containing Esomerpazole And Method Of Preparation
WO2004098573A1 (fr) Composition pharmaceutique amelioree et stable contenant des benzimidazoles substitues et son procede de preparation
WO2005034924A1 (fr) Pastilles a enrobage enterique comprenant de l'esomeprazole, capsule de gelatine dure renfermant celles-ci et procede de preparation associe
CA2392353A1 (fr) Compositions pharmaceutiques stables au benzimidazole labile acide
CZ295266B6 (cs) Stabilní galenické přípravky obsahující benzimidazol a způsob jejich přípravy
WO2009113090A2 (fr) Procédé de préparation d’une formule orale d’un médicament à base de benzimidazole sensible à l’acide

Legal Events

Date Code Title Description
FZDE Discontinued